Global Instability Impacting Generic Pharmaceutical Sustainability in Portugal
Global Instability Impacting Generic Pharmaceutical Sustainability in Portugal

By João L. Carapinha

July 8, 2026

Global instability impacting generic pharmaceutical sustainability has become a pressing challenge for Portugal, where rising international conflicts are undermining the economic viability of generic drug production. After 34 years of ensuring affordable access to essential treatments, these medi...
BFI Healthcare Procurement South Africa Driving Infrastructure Advancements
BFI Healthcare Procurement South Africa Driving Infrastructure Advancements
South Africa’s healthcare system stands at a pivotal moment as BFI healthcare procurement accelerates the delivery of modern hospitals and clinics. The Department of Health is preparing 11 formal bids for the Budget Facility for Infrastructure (BFI), signalling a decisive shift from slow annual a...
Omaveloxolone Appropriate Utilization Consensus Framework for Friedreich Ataxia
Omaveloxolone Appropriate Utilization Consensus Framework for Friedreich Ataxia
The omaveloxolone appropriate utilization consensus delivers a tightly controlled framework for using Skyclarys in Friedreich’s ataxia, restricting initiation and discontinuation decisions to two specialized Dutch centers. By combining validated functional scales with strict safety thresholds and...
Conditional Adoption Pathways for Endometriosis Diagnostics
Conditional Adoption Pathways for Endometriosis Diagnostics
The introduction of conditional adoption pathways for endometriosis offers a structured route to faster diagnosis for the millions of women facing four-to-ten-year delays within the NHS. N...
Biologic Dispensing Implementation Gaps Challenge Patient Access to Care
Biologic Dispensing Implementation Gaps Challenge Patient Access to Care

By João L. Carapinha

July 7, 2026

Biologic dispensing implementation gaps are undermining equitable access to advanced therapies for inflammatory bowel disease across Portugal’s public hospitals. Despite clear legislative changes, institutions continue to reject prescriptions for biologics written by private specialists, forcing ...
Curative Therapy Commercialization Gap and Global Access Challenges
Curative Therapy Commercialization Gap and Global Access Challenges
The curative therapy commercialization gap remains one of healthcare’s most stubborn contradictions: cell and gene therapies can deliver complete disease resolution, yet structural, financial, and infrastructural barriers keep them from reaching most patients who need them. This disconnect is esp...
Search By Category
Curative Therapy Commercialization Gap and Global Access Challenges

Global Updates

Curative Therapy Commercialization Gap and Global Access Challenges
The curative therapy commercialization gap remains one of healthcare’s most stubborn contradictions: cell and gene therapies can deliver complete disease resolution, yet structural, financial, and infrastructural barriers keep them from reaching most patients who need them. This disconnect is esp...
Impact of Practice-Level Telehealth on Quality Outcomes in Chronic Care

Global Updates

Impact of Practice-Level Telehealth on Quality Outcomes in Chronic Care

By João L. Carapinha

July 6, 2026

Practice-level telehealth quality outcomes remained stable for access and preventable hospitalizations among Medicare beneficiaries with chronic conditions during the COVID-19 pandemic. High-adopting primary care practices preserved care continuity while delivering modestly lower performance on s...
Large Language Models in Evidence-Based Medicine

Global Updates

Large Language Models in Evidence-Based Medicine

By João L. Carapinha

July 3, 2026

Large language models deliver rapid synthesis of medical literature, but according to research on fast information and slow evidence, they cannot independently generate validated evidence for clinical decisions. These tools sit at a...
Retracted Trial Publication Undermines Support for Avacopan in AAV Treatment

Global Updates

Retracted Trial Publication Undermines Support for Avacopan in AAV Treatment

By João L. Carapinha

July 1, 2026

The Retracted Trial Publication of the ADVOCATE study has eliminated the central evidence that supported approval of Tavneos (avacopan) for severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis (AAV). At the request of two lead academic authors, the

Upcoming Global Events

Upcoming Events:
August 29-September 2, 2026 42nd Annual ISPE Meeting | Milan, Italy Website →
September 3-4, 2026 13th RWE, Market Access, Pricing & Reimbursement 2026 Europe | Hilton London Kensington, London, UK Website →
September 6-8, 2026 ISPOR Asia Pacific Summit 2026 | Bangkok, Thailand Website →